Top

International Journal of Colorectal Disease

Published in:

01-03-2021 | Rectal Cancer | Original Article

Downstaged ypT0-2N0 rectal cancer after neoadjuvant chemoradiation therapy may not need adjuvant chemotherapy: a retrospective cohort study

Authors: Yu-Tso Liao, Yu-Lin Lin, John Huang, Ji-Shiang Hung, Been-Ren Lin

Published in: International Journal of Colorectal Disease | Issue 3/2021

Abstract

Purpose

Current guidelines suggest that adjuvant chemotherapy (AC) be administered to all locally advanced (clinically T3–4 or N-positivity) rectal cancer patients undergoing neoadjuvant chemoradiotherapy (nCRT) and radical surgical resection regardless of the final pathological staging (yp staging). This study aimed to evaluate the necessity of AC for ypT0-2N0 rectal cancer.

Methods

Patients with ypT0-2N0 rectal cancer, who received nCRT and radical surgical resection, were recruited retrospectively at a university hospital. The main outcome was to evaluate the 5-year overall survival (OS) and disease-free survival (DFS) between ypT0-2N0 rectal cancer patients with AC and those without AC. We also identified potential independent prognostic factors associated with poor outcomes.

Results

One hundred and ten ypT0-2N0 rectal cancer patients (ypT0: n = 6; ypT1: n = 44; ypT2: n = 60) were followed up for a median of 60 months. No significant difference was observed in DFS and 5-year OS between patients with AC and those without AC. The risk of recurrence was associated with the postoperative pathological staging (0% with ypT0, 2.4% with ypT1, and 10% with ypT2). In the multivariate analysis, retrieval of < 12 lymph nodes was an independent favorable prognostic factor, which correlated with a higher OS (HR: 2.263; 95% CI: 1.093–4.687, P = 0.028). Intra-tumor lymphovascular and perineural invasion were poor prognostic markers for shorter DFS (HR: 5.940; 95% CI: 1.150–30.696, P = 0.033).

Conclusion

Postoperative AC is not required for patients with ypT0-2N0 rectal cancer downstaged by nCRT, especially in those without poor prognostic factors.

Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30:1926–1933. https://doi.org/10.1200/JCO.2011.40.1836CrossRefPubMed

National Comprehensive Cancer Network (2020) Rectal cancer (Version 2.2020). https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed 3 March 2020

van Gijn W, Marijnen CA, Nagtegaal IDT et al (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12:575–582. https://doi.org/10.1016/S1470-2045(11)70097-3CrossRefPubMed

Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC, EORTC Radiotherapy Group Trial 22921 (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 55:1114–1123. https://doi.org/10.1056/NEJMoa060829CrossRef

Madbouly KM, Hussein AM (2015) Changing operative strategy from abdominoperineal resection to sphincter preservation in T3 low rectal cancer after downstaging by neoadjuvant chemoradiation: a preliminary report. World J Surg 39:1248–1256. https://doi.org/10.1007/s00268-014-2930-3CrossRefPubMed

Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, Fisher ER, Caplan R, Jones J, Lerner H, Gordon P, Feldman M, Cruz A, Legault-Poisson S, Wexler M, Lawrence W, Robidoux A, Other NSABP Investigators (1988) Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 80:21–29. https://doi.org/10.1093/jnci/80.1.21CrossRefPubMed

Wolpin BM, Mayer RJ (2008) Systemic treatment of colorectal cancer. Gastroenterology 134:1296–1310. https://doi.org/10.1053/j.gastro.2008.02.098CrossRefPubMed

Andre T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116. https://doi.org/10.1200/JCO.2008.20.6771CrossRefPubMed

Hess V, Winterhalder R, von Moos R et al (2017) Capecitabine and oxaliplatin prior and concurrent to preoperative pelvic radiotherapy in patients with locally advanced rectal cancer: long-term outcome. Clin Colorectal Cancer 16:240–245. https://doi.org/10.1016/j.clcc.2016.07.008CrossRefPubMed

10.

Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M, Pucciarelli S, Small W Jr, Suárez J, Theodoropoulos G, Biondo S, Beets-Tan RGH, Beets GL (2010) Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11:835–844. https://doi.org/10.1016/S1470-2045(10)70172-8CrossRefPubMed

11.

Gamaleldin M, Church JM, Stocchi L, Kalady M, Liska D, Gorgun E (2017) Is routine use of adjuvant chemotherapy for rectal cancer with complete pathological response justified. Am J Surg 213:478–483. https://doi.org/10.1016/j.amjsurg.2016.11.028CrossRefPubMed

12.

Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, Radosevic-Jelic L, Piérart M, Calais G (2007) Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 25:4379–4386. https://doi.org/10.1200/JCO.2007.11.9685CrossRefPubMed

13.

Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, Bardet E, Beny A, Ollier JC, Bolla M, Marchal D, van Laethem JL, Klein V, Giralt J, Clavère P, Glanzmann C, Cellier P, Collette L (2014) Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15:184–190. https://doi.org/10.1016/S1470-2045(13)70599-0CrossRefPubMed

14.

Breugom AJ, van Gijn W, Muller EW, Berglund Å, van den Broek CBM, Fokstuen T, Gelderblom H, Kapiteijn E, Leer JWH, Marijnen CAM, Martijn H, Meershoek-Klein Kranenbarg E, Nagtegaal ID, Påhlman L, Punt CJA, Putter H, Roodvoets AGH, Rutten HJT, Steup WH, Glimelius B, van de Velde CJH (2015) Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo) radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 26:696–701. https://doi.org/10.1093/annonc/mdu560CrossRefPubMed

15.

Glynne-Jones R, Counsell N, Quirke P et al (2014) Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 251:356–1362. https://doi.org/10.1093/annonc/mdu147CrossRef

16.

Sainato A, Cernusco Luna Nunzia V, Valentini V, de Paoli A, Maurizi ER, Lupattelli M, Aristei C, Vidali C, Conti M, Galardi A, Ponticelli P, Friso ML, Iannone T, Osti FM, Manfredi B, Coppola M, Orlandini C, Cionini L (2014) No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Onco 113:223–229. https://doi.org/10.1016/j.radonc.2014.10.006CrossRef

17.

Govindarajan A, Reidy D, Weiser MR, Paty PB, Temple LK, Guillem JG, Saltz LB, Wong WD, Nash GM (2011) Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision. Ann Surg Oncol 18:3666–3672. https://doi.org/10.1245/s10434-011-1788-yCrossRefPubMed

18.

You KY, Huang R, Ding PR, Qiu B, Zhou GQ, Chang H, Xiao WW, Zeng ZF, Pan ZZ, Gao YH (2014) Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0. Int J Colorectal Dis 29:529–538. https://doi.org/10.1007/s00384-014-1831-0CrossRefPubMedPubMedCentral

19.

Bujko K, Glynne-Jones R, Bujko M (2010) Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol 21:1743–1750. https://doi.org/10.1093/annonc/mdq054CrossRefPubMed

20.

Dossa F, Acuna SA, Rickles AS, Berho M, Wexner SD, Quereshy FA, Baxter NN, Chadi SA (2018) Association between adjuvant chemotherapy and overall survival in patients with rectal cancer and pathological complete response after neoadjuvant chemotherapy and resection. JAMA Oncol 4:930–937. https://doi.org/10.1001/jamaoncol.2017.5597CrossRefPubMedPubMedCentral

21.

Polanco P, Huerta S (2018) Omitting adjuvant chemotherapy in patients with rectal cancer who received neoadjuvant chemoradiation followed by total mesorectal excision and achieved a pathological complete response. Am J Surg 216:387–388. https://doi.org/10.1016/j.amjsurg.2017.03.019CrossRefPubMed

22.

Garlipp B, Ptok H, Benedix F, Otto R, Popp F, Ridwelski K, Gastinger I, Benckert C, Lippert H, Bruns C (2016) Adjuvant treatment for resected rectal cancer: impact of standard and intensified postoperative chemotherapy on disease-free survival in patients undergoing preoperative chemoradiation-a propensity score-matched analysis of an observational database. Langenbecks Arch Surg 401:1179–1190. https://doi.org/10.1007/s00423-016-1530-0CrossRefPubMed

23.

Tiselius C, Gunnarsson U, Smedh K, Glimelius B, Pahlman L (2013) Patients with rectal cancer receiving adjuvant chemotherapy have an increased survival: a population-based longitudinal study. Ann Oncol 24:160–165. https://doi.org/10.1093/annonc/mds278CrossRefPubMed

24.

Martin ST, Heneghan HM, Winter DC (2012) Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg 99:918–928. https://doi.org/10.1002/bjs.8702CrossRefPubMed

25.

Kuo LJ, Liu MC, Jian JJ et al (2007) Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy. Ann Surg Oncol 14:2766–2772. https://doi.org/10.1245/s10434-007-9471-zCrossRefPubMed

26.

Kim YW, Kim NK, Min BS, Lee KY, Sohn SK, Cho CH (2009) The influence of the number of retrieved lymph nodes on staging and survival in patients with stage II and III rectal cancer undergoing tumor-specific mesorectal excision. Ann Surg 249:965–972. https://doi.org/10.1097/SLA.0b013e3181a6cc25CrossRefPubMed

27.

Tsai CJ, Crane CH, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Feig BW, Eng C, Krishnan S, Maru DM, Das P (2011) Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer 117:3713–3722. https://doi.org/10.1002/cncr.25973CrossRefPubMed

28.

de Campos-Lobato LF, Stocchi L, de Sousa JB, Buta M, Lavery IC, Fazio VW, Dietz DW, Kalady MF (2013) Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think. Ann Surg Oncol 20:3398–3406. https://doi.org/10.1245/s10434-013-3010-xCrossRefPubMed

29.

Persiani R, Biondi A, Gambacorta MA, Bertucci Zoccali M, Vecchio FM, Tufo A, Coco C, Valentini V, Doglietto GB, D'Ugo D (2014) Prognostic implications of the lymph node count after neoadjuvant treatment for rectal cancer. Br J Surg 101:133–142. https://doi.org/10.1002/bjs.9341CrossRefPubMed

30.

Fajardo LF (1994) Effects of ionizing radiation on lymph nodes. A review. Front Radiat Ther Oncol 28:37–45. https://doi.org/10.1159/000423371CrossRefPubMed

31.

Yao YF, Wang L, Liu YQ, Li JY, Gu J (2011) Lymph node distribution and pattern of metastases in the mesorectum following total mesorectal excision using the modified fat clearing technique. J Clin Pathol 64:1073–1077. https://doi.org/10.1136/jclinpath-2011-200190CrossRefPubMed

32.

Lin BR, Lai HS, Chang TC, Lee PH, Chang KJ, Liang JT (2011) Long-term survival results of surgery alone versus surgery plus UFT (Uracil and Tegafur)-based adjuvant therapy in patients with stage II colon cancer. J Gastrointest Surg 15:2239–22345. https://doi.org/10.1007/s11605-011-1722-4CrossRefPubMed

33.

Park IJ, Yu CS, Lim SB, Yoon YS, Kim CW, Kim TW, Kim JH, Kim JC (2014) Prognostic implications of the number of retrieved lymph nodes of patients with rectal cancer treated with preoperative chemoradiotherapy. J Gastrointest Surg 18:1845–18451. https://doi.org/10.1007/s11605-014-2509-1CrossRefPubMed

Title: Downstaged ypT0-2N0 rectal cancer after neoadjuvant chemoradiation therapy may not need adjuvant chemotherapy: a retrospective cohort study
Authors: Yu-Tso Liao
Yu-Lin Lin
John Huang
Ji-Shiang Hung
Been-Ren Lin
Publication date: 01-03-2021
Publisher: Springer Berlin Heidelberg
Keywords: Rectal Cancer
Rectal Cancer
Cytostatic Therapy
Published in: International Journal of Colorectal Disease / Issue 3/2021
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-020-03787-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Downstaged ypT0-2N0 rectal cancer after neoadjuvant chemoradiation therapy may not need adjuvant chemotherapy: a retrospective cohort study

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2021

Single-incision laparoscopic surgery (SILS) for the treatment of ileocolonic Crohn’s disease: a propensity score–matched analysis

Appendectomy in childhood—did it save my sibling from getting ulcerative colitis?

Risk of lymph node metastasis after endoscopic treatment for rectal NETs 10 mm or less

Fecal-oral transmission of SARS-CoV-2: review of laboratory-confirmed virus in gastrointestinal system

Clinical outcome and quality of life after gracilis muscle transposition for fistula closure over a 10-year period

Are colorectal cancer patients at risk for COVID-19 infection during the postoperative period? The Covid-GRECCAR study